DDInter259 DDInter1435
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Cabazitaxel {u} (Compound) resembles {v} (Compound) Docetaxel
Cabazitaxel {u} (Compound) treats {v} (Disease) prostate cancer
Cabazitaxel {u} (Compound) binds {v} (Gene) CYP3A5
Cabazitaxel {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Cabazitaxel {u} (Compound) causes {v} (Side Effect) Cardiac failure
Cabazitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Cabazitaxel {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Cabazitaxel {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Cabazitaxel (Compound) resembles Docetaxel (Compound)
Cabazitaxel (Compound) treats prostate cancer (Disease)
Cabazitaxel (Compound) binds CYP3A5 (Gene)
Cabazitaxel (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Cabazitaxel (Compound) causes Cardiac failure (Side Effect)
Cabazitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Cabazitaxel may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Cabazitaxel may lead to a major life threatening interaction when taken with Clozapine